Class / Patent application number | Description | Number of patent applications / Date published |
424183100 | Conjugated to proteinaceous toxin or fragment thereof (e.g., conjugated to diphtheria toxin, Pseudomonas exotoxin, ricin, gelonin, abrin, etc.) | 50 |
20090022745 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof - Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof. | 01-22-2009 |
20090053248 | Compositions and methods for transepithelial molecular transport - The invention relates to fragments of | 02-26-2009 |
20090226468 | Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the CNS - The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e. retrograde transynaptic transport of the TTC fragment and -gal enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy is useful for the delivery of a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein can also be used to map synaptic connections between neural cells. | 09-10-2009 |
20090269361 | Constructs for delivery of therapeutic agents to neuronal cells - A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a H | 10-29-2009 |
20090280134 | COMPOSITIONS AND METHODS FOR INHIBITING TOXIN A FROM CLOSTRIDIUM DIFFICILE - The present invention provides compositions and methods for treating or preventing infection by Toxin A producing bacteria. | 11-12-2009 |
20090304721 | TOXIN CONJUGATED EPH RECEPTOR ANTIBODIES - The present invention relates to compositions and methods for inducing cell death or stasis in cancer cells or other hyperproliferative cells using anti-EphA2 or anti-EphA4 antibodies conjugated to toxins. | 12-10-2009 |
20100111978 | CONJUGATES BETWEEN A VARIANT STAPHYLOCOCCAL ENTEROTOXIN E SUPERANTIGEN AND A TARGETING ANTIBODY THAT BINDS TO A CANCER-ASSOCIATED CELL SURFACE STRUCTURE - The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity. | 05-06-2010 |
20100111979 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. | 05-06-2010 |
20100233191 | Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins - The present invention provides a method of treating BPH using modified pore-forming proteins (MPPs). These MPPs are derived from naturally occurring cytotoxic proteins (nPPs) that kill cells by forming pores or channels in the cell membrane, resulting in cell death. The MPPs are generated by modification of the nPPs such that they are capable of being selectively activated at normal prostate cells. Such modification may include the addition of a prostate-specific protease cleavage site to the activation sequence, and/or the addition of a prostate-specific targeting domain to allow selective targeting of prostate cells. These MPPs are capable of selectively targeting and killing normal prostate cells in vivo. The MPPs may be used either alone or in combination with other therapies for the treatment of BPH. | 09-16-2010 |
20100303836 | TREATMENT OF HYPERPROLIFERATIVE DISEASE WITH SUPERANTIGENS IN COMBINATION WITH ANOTHER ANTICANCER AGENT - The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal. | 12-02-2010 |
20110142860 | Depletion of CD103 Expressing Cells for Treatment of Disorders - The present invention relates to methods of selectively depleting CD103+ cells in vivo in a subject, with the methods comprising administering a composition comprising an anti-CD103 antibody conjugated to a lethal compound to the subject. | 06-16-2011 |
20110142861 | DEPLETION OF CD103 EXPRESSING CELLS FOR TREATMENT OF DISORDERS - The present invention relates to methods of selectively depleting CD103+ cells in vivo in a subject, with the methods comprising administering a composition comprising an anti-CD103 antibody conjugated to a lethal compound to the subject. | 06-16-2011 |
20110177104 | METHOD FOR SELECTIVE DEPLETION OF CD137 POSITIVE CELLS USING ANTI-CD137 ANTIBODY-TOXIN COMPLEX - The present invention relates to method for depletion of CD137 positive cells using an anti-CD137 antibody-toxin complex, and more particularly, to a method for selective depletion of CD137 positive cells, comprising the step of contacting an anti-CD137 antibody-toxin complex with the CD137 positive cells. The method for selective depletion of CD137 positive cells in accordance with the present invention can be useful to prevent or treat various diseases including immune diseases mediated by the activation of the CD137 positive cells because this method is excellent in delivering a complex of an anti-CD137 antibody, specific to CD137 molecules, and a toxin to CD137 expressing cells and selectively killing the CD137 positive cells alone and is also excellent in suppressing cell proliferation. | 07-21-2011 |
20110189209 | FOLD-BACK DIABODY DIPHTHERIA TOXIN IMMUNOTOXIN AND METHODS OF USE - Provided are methods and compositions related to diphtheria toxin diabody immunotoxins. | 08-04-2011 |
20110280892 | TOXIN CONJUGATED EPH RECEPTOR ANTIBODIES - The present invention relates to compositions and methods for inducing cell death or stasis in cancer cells or other hyperproliferative cells using anti-EphA2 or anti-EphA4 antibodies conjugated to toxins. | 11-17-2011 |
20110293639 | IDEOTYPICALLY MODULATED PHARMACOEFFECTORS FOR SELECTIVE CELL TREATMENT - In a method embodiment, a method includes introducing a plurality of Ideotypically Modulated Pharmacoeffectors (IMP) into a population of cells. Each IMP may include a detection domain and an activation domain. One or more epitopes is bound by the detection domain. The activation domain is activated in response to the binding. Applications may include but are not limited to viral infections, other intracellular infections, cancers, vector-borne diseases, autoimmune diseases, cellular diseases, cellular enhancement, and research. | 12-01-2011 |
20110300163 | IgE CH3 Peptide Vaccine - The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine. | 12-08-2011 |
20120027785 | CHIMERA COMPRISING BACTERIAL CYTOTOXIN AND METHODS OF USING THE SAME - This invention provides, a recombinant polypeptide encoding a chimera. The chimera includes a DNase I fragment or a homologue thereof and a Cdt fragment or a homologue thereof. Further, the invention provides methods, utilizing the recombinant polypeptide encoding the chimera, such as a method for inhibiting the proliferation of a neoplastic cell, a method for treating a neoplastic disease in a human subject, a method for inhibiting or suppressing a neoplastic disease in a human subject, and a method for reducing the symptoms associated with a neoplastic disease in a human subject. | 02-02-2012 |
20120100161 | Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy - The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer. | 04-26-2012 |
20120141511 | CLOSTRIDIAL TOXIN DERIVATIVES ABLE TO MODIFY PERIPHERAL SENSORY AFFERENT FUNCTIONS - A novel agent for the targeted control of a mammalian cell activity can be used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E, linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain, which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome; Domain T is the Translocation Domain, which translocates the agent from within the endosome across the endosomal membrane into the cytosol of the cell; and Domain E is the Effector Domain, which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell. | 06-07-2012 |
20120213805 | Amatoxin-Armed Tartget-Binding Moieties for the Treatment of Cancer - The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of target-binding moieties and toxins that are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moieties (e.g. antibodies) are directed against tumour-associated antigens, such as epithelial cell adhesion molecule (EpCAM). In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer, in particular adenocarcinoma, such as pancreatic cancer, cholangiocarcinoma, breast cancer, and colorectal cancer. | 08-23-2012 |
20120237533 | Compositions and Methods for Inducing Apoptosis in Prostate Cancer Cells - Compositions and methods for inhibiting the growth of cancer cells, particularly prostate cancer cells are disclosed. | 09-20-2012 |
20130202626 | METHOD FOR PURIFYING ACTIVE POLYPEPTIDES OR IMMUNOCONJUGATES - The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. | 08-08-2013 |
20130236479 | ANTIGEN - The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described. | 09-12-2013 |
20140017266 | ANTI-PODOPLANIN ANTIBODIES AND METHODS OF USE - Recombinant scFv-immunotoxins target tumor cells expressing human podoplanin but not podoplanin-negative or normal cells. The immunotoxins can be used for treatment of malignant glioma patients or any malignant tumor expressing podoplanin. One such immunotoxin comprises a modified | 01-16-2014 |
20140127241 | ANTIBODY/DRUG CONJUGATES AND METHODS OF USE - The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target. | 05-08-2014 |
20140178417 | METHODS FOR TREATING CANCER USING AN IMMUNOTOXIN - The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotixin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of | 06-26-2014 |
20140205617 | Compositions and Methods for Treatment of Neoplastic Disease - The present invention comprises the use of sickle cells or sickle cell precursors loaded with a therapeutic agent that localize in tumors and induce a tumoricidal response. | 07-24-2014 |
20140322248 | Dual Specific Immunotoxin for Brain Tumor Therapy - We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors. | 10-30-2014 |
20140335109 | COMBINATION OF INOTUZUMAB OZOGAMICIN AND TORISEL FOR THE TREATMENT OF CANCER - The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination of inotuzumab ozogamicin (CMC-544) and temsirolimus. The enhanced antitumor of the combination therapy is particularly useful for patient population that are recalcitrant to inotuzumab ozogamicin or temsirolimus therapy, relapse after treatment with inotuzumab ozogamicin or temsirolimus or where enhanced antitumor effect reduces toxicities associated with treatment using inotuzumab ozogamicin or temsirolimus. | 11-13-2014 |
20150079116 | DIAGNOSTIC TOOLS FOR RESPONSE TO 6-THIOPURINE THERAPY - NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein. | 03-19-2015 |
20150118256 | IGE CH3 Peptide Vaccine - The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine. | 04-30-2015 |
20150140023 | USE OF MONOCLONAL ANTIBODIES SPECIFIC TO THE O-ACETYLATED FORM OF GD2 GANGLIOSIDE FOR THE TREATMENT OF CERTAIN CANCERS - The monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of the antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, the antibody or the fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. Also artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2. | 05-21-2015 |
20150291667 | CHIMERA COMPRISING BACTERIAL CYTOTOXIN AND METHODS OF USING THE SAME - This invention provides, a recombinant polypeptide encoding a chimera. The chimera includes a DNase I fragment or a homologue thereof and a Cdt fragment or a homologue thereof. Further, the invention provides methods, utilizing the recombinant polypeptide encoding the chimera, such as a method for inhibiting the proliferation of a neoplastic cell, a method for treating a neoplastic disease in a human subject, a method for inhibiting or suppressing a neoplastic disease in a human subject, and a method for reducing the symptoms associated with a neoplastic disease in a human subject. | 10-15-2015 |
20150337042 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES - The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs. | 11-26-2015 |
20150343087 | Class I Anti-CEA Antibodies and Uses Thereof - The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer. | 12-03-2015 |
20160002298 | AMATOXIN DERIVATIVES - The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer and other disorders and diseases. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates. | 01-07-2016 |
20160024159 | POTENT AND SELECTIVE INHIBITORS OF NAV1.7 - Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na | 01-28-2016 |
20160058885 | Antibodies With Immune Effector Activity and that Internalize In Folate Receptor Alpha-positive Cells - This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies. | 03-03-2016 |
20160089450 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY - The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer. | 03-31-2016 |
20160122430 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES - The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma. | 05-05-2016 |
20160136287 | CONJUGATED VACCINE - The present invention provides a composition for provoking an immune response in a patient to an autoantigen target, the composition comprising the target conjugated a carrier polypeptide. | 05-19-2016 |
20160136297 | TARGETING ABCB5 FOR CANCER THERAPY - The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof. | 05-19-2016 |
20160136298 | METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE - A method of producing an immunoligand/payload conjugate can encompass conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof. | 05-19-2016 |
20160136300 | ANTIBODY-DRUG CONJUGATE HAVING IMPROVED STABILITY AND USE THEREOF - The present invention relates to an antibody-drug conjugate comprising a drug conjugated to an antibody, a preparation method thereof and the use thereof. | 05-19-2016 |
20160145338 | HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR CD22 - Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (K | 05-26-2016 |
20160151489 | COMBINATION OF A LIGAND OF HVEM AND AN IMMUNOTOXIN FOR USE IN THERAPY | 06-02-2016 |
20160193358 | ANTIGEN BINDING PROTEINS | 07-07-2016 |
20160199507 | METHODS FOR TREATING CANCER USING AN IMMUNOTOXIN | 07-14-2016 |
20160250351 | Treating Lymphomas | 09-01-2016 |